Meditation therapies for attention-deficit/hyperactivity disorder (ADHD)

Department of Psychiatry, Faculty of Medicine, KhonKaen University, KhonKaen, Thailand, 40002.
Cochrane database of systematic reviews (Online) (Impact Factor: 5.94). 06/2010; 6(6):CD006507. DOI: 10.1002/14651858.CD006507.pub2
Source: PubMed

ABSTRACT Attention-deficit/hyperactivity disorder (ADHD) is a disorder that affects a significant number of children and adults in a variety of ways. It is characterized by chronic levels of inattention, impulsiveness and hyperactivity. Meditation therapy could be a beneficial treatment for those diagnosed with ADHD. The objective of this review was to assess the efficacy of this treatment. As a result of the small number of studies that we were able to include in this review and the limitations of those studies, we were unable to draw any conclusions regarding the effectiveness of meditation therapy for ADHD. No adverse effects of meditation in children have been reported. More trials are needed on meditation therapies for ADHD so that conclusions can be drawn regarding its effectiveness.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is an ongoing project. Special thanks to Christopher Germer, Ph.D. and the Institute for Meditation and Psychotherapy for their many contributions. This bibliography does not try to include all the references to the broader Buddhist/therapy dialogue, which would extend it considerably. Also, more complete references for mindfulness in relation to physical and medical conditions, as well as neuroscience and physiological effects of mindfulness can be found in John C. Williams and Lidia Zylowska's "Mindfulness Bibliography. From molecules to mindfulness: Howe vertically convergent fractal time fluctuations unify cognition and emotion. Consciousness & Emotion, 1, 193-226.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abnormal dopamine (DA) transporter functioning has long been suspected to be involved in attention-deficit hyperactivity disorder (ADHD). My extensive search on theories concerning ADHD included: CENTRAL, MEDLINE, EMBASE, CINAHL, ERIC, PsycINFO, Complementary and Alternative Medicine-specific databases, Informit, JST, plus grey literature and trial registries from inception to May 2010. A new understanding of ADHD pathophysiology is required. DA-deficit theory of ADHD is insufficient to cover critical aspects of ADHD pathology and medication. The dominance of this theory discourages the human and financial investments needed to explore alternative theories and has caused an evident bias in health and drug policies. A combined theory of altered DA and serotonin (5HT), deficit DA, and weakened prefrontal cortex (PFC) circuits may serve as a good alternate to DA-theory alone. This combined theory may influence the future of drug polices, pharmaceutical investments, treatment options, and drug developments.
    ADHD Attention Deficit and Hyperactivity Disorders 11/2010; 2(3):149-57. DOI:10.1007/s12402-010-0033-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Physiological differences between children and adults result in age-related differences in pharmacokinetics and drug effect. In neonates and infants, decreased weight-adjusted doses are required because of decreased protein binding, renal excretion, and/or metabolism. For children older than 1 year of age, significantly higher weight-corrected doses compared with adults are needed for drugs eliminated by the cytochrome P450 (CYP) isozymes CYP1A2, CYP2C9, and CYP3A4. In contrast, weight-corrected doses for drugs eliminated by renal excretion or metabolism by CYP2C19, CYP2D6, N-Acetyl-transferase, and UDP glucuronosyltransferase in children are similar to those in adults. Ideally, pharmacokinetic and pharmacodynamic data should be available for all drugs used in children. Because many drugs are not approved for pediatric use, data are often limited, especially for older drugs. Understanding the effects of age on pharmacokinetics can help to determine appropriate pediatric dosing in situations in which there is limited information.
    Seminars in pediatric neurology 12/2010; 17(4):208-13. DOI:10.1016/j.spen.2010.10.002 · 1.88 Impact Factor
Show more


Available from